Suppr超能文献

严重联合免疫缺陷的临床、免疫学和分子特征:来自印度的多机构经验。

Clinical, Immunological, and Molecular Features of Severe Combined Immune Deficiency: A Multi-Institutional Experience From India.

机构信息

Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Bone Marrow Transplantation Unit, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

出版信息

Front Immunol. 2021 Feb 8;11:619146. doi: 10.3389/fimmu.2020.619146. eCollection 2020.

Abstract

BACKGROUND

Severe Combined Immune Deficiency (SCID) is an inherited defect in lymphocyte development and function that results in life-threatening opportunistic infections in early infancy. Data on SCID from developing countries are scarce.

OBJECTIVE

To describe clinical and laboratory features of SCID diagnosed at immunology centers across India.

METHODS

A detailed case proforma in an Excel format was prepared by one of the authors (PV) and was sent to centers in India that care for patients with primary immunodeficiency diseases. We collated clinical, laboratory, and molecular details of patients with clinical profile suggestive of SCID and their outcomes. Twelve (12) centers provided necessary details which were then compiled and analyzed. Diagnosis of SCID/combined immune deficiency (CID) was based on 2018 European Society for Immunodeficiencies working definition for SCID.

RESULTS

We obtained data on 277 children; 254 were categorized as SCID and 23 as CID. Male-female ratio was 196:81. Median (inter-quartile range) age of onset of clinical symptoms and diagnosis was 2.5 months (1, 5) and 5 months (3.5, 8), respectively. Molecular diagnosis was obtained in 162 patients - (36), (26), (19), (17), (15), (13), (9), (3), (3), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), and (1). Only 23 children (8.3%) received hematopoietic stem cell transplantation (HSCT). Of these, 11 are doing well post-HSCT. Mortality was recorded in 210 children (75.8%).

CONCLUSION

We document an exponential rise in number of cases diagnosed to have SCID over the last 10 years, probably as a result of increasing awareness and improvement in diagnostic facilities at various centers in India. We suspect that these numbers are just the tip of the iceberg. Majority of patients with SCID in India are probably not being recognized and diagnosed at present. Newborn screening for SCID is the need of the hour. Easy access to pediatric HSCT services would ensure that these patients are offered HSCT at an early age.

摘要

背景

严重联合免疫缺陷(SCID)是一种淋巴细胞发育和功能的遗传性缺陷,导致婴儿期危及生命的机会性感染。关于发展中国家 SCID 的数据很少。

目的

描述印度各地免疫学中心诊断的 SCID 的临床和实验室特征。

方法

由作者之一(PV)编写了一个详细的病例表格,并将其发送给印度照顾原发性免疫缺陷疾病患者的中心。我们收集了具有 SCID 临床特征且有结局的患者的临床、实验室和分子详细信息。12 个中心提供了必要的详细信息,然后进行了编译和分析。SCID/联合免疫缺陷(CID)的诊断基于 2018 年欧洲免疫缺陷学会 SCID 工作定义。

结果

我们获得了 277 名儿童的数据;254 名被归类为 SCID,23 名被归类为 CID。男女比例为 196:81。临床症状和诊断的中位(四分位距)发病年龄分别为 2.5 个月(1,5)和 5 个月(3.5,8)。在 162 名患者中获得了分子诊断- (36)、 (26)、 (19)、 (17)、 (15)、 (13)、 (9)、 (3)、 (3)、 (2)、 (2)、 (2)、 (2)、 (2)、 (2)、 (2)、 (1)、 (1)、 (1)、 (1)、 (1)、 (1)。只有 23 名儿童(8.3%)接受了造血干细胞移植(HSCT)。其中 11 人在 HSCT 后情况良好。210 名儿童(75.8%)记录了死亡。

结论

我们记录了过去 10 年中诊断为 SCID 的病例数量呈指数级增长,这可能是由于印度各地各中心的认识和诊断设施不断提高。我们怀疑这些数字只是冰山一角。目前,印度大多数 SCID 患者可能未被识别和诊断。SCID 的新生儿筛查是当务之急。容易获得儿科 HSCT 服务将确保这些患者在早期接受 HSCT。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验